



10 April 2018

## ASX Announcement

### Penthrox is approved in Canada

Medical Developments International Limited (ASX:MVP), announce today that PENTHROX<sup>®</sup>, has been granted Market Authorisation in Canada. The Marketing Authorisation issued by Health Canada allows PENTHROX<sup>®</sup> to be used for the short-term relief of moderate to severe acute pain, associated with trauma or interventional medical procedures, in conscious adult patients<sup>1</sup>.

**John Sharman**, Chief Executive Officer, Medical Developments International Ltd: “The global expansion of PENTHROX<sup>®</sup> is gaining momentum. PENTHROX<sup>®</sup> has been a key treatment in the relief of trauma pain with more than six million administrations worldwide<sup>2</sup>. We’re proud to have a partner, like Purdue, with a long and successful legacy in treating pain, now making PENTHROX<sup>®</sup> available to Canadian patients who are suffering from moderate to severe acute pain due to trauma or undergoing interventional medical procedures.”

Mr Sharman said: “Under the terms of the exclusive agreement between the companies, Purdue Pharma (Canada) has the exclusive right to register, market, promote, distribute and sell PENTHROX<sup>®</sup> in Canada. MDI will retain clinical development activities, as well as the manufacture and supply of PENTHROX<sup>®</sup> to Purdue Pharma (Canada).”

**Dr. Tom Koutsavlis, Vice President, Research and Development (R&D), Purdue Pharma (Canada), commented:** “From my experience, a non-invasive, fast-acting, treatment option that does not require opioid-associated monitoring, like PENTHROX<sup>®</sup>, is necessary. PENTHROX<sup>®</sup> has the added benefit of being a lightweight, portable, handheld inhaler which is also patient-controlled. Not only has it been shown to be safe and effective, it can also help simplify trauma treatments for both patients and their caregivers.”

**David Pidduck, President and CEO, Purdue Pharma (Canada), commented:** “As a leader in pain management, we remain steadfast in our commitment to improving the lives of Canadian patients suffering from pain. We’re excited to add PENTHROX<sup>®</sup> to our existing product portfolio and will continue on our promise to directly support the pain treatment landscape across this country.”

Enquiries:

David Williams  
Chairman  
Medical Developments International Ltd  
+61 (0) 414 383 593

John Sharman  
Chief Executive Officer  
Medical Developments International Ltd  
+61 (3) 9547 1888

Sarah L. Robertson, Director of Communications  
Purdue Pharma (Canada),  
Pickering, ON, Canada [media@purdue.ca](mailto:media@purdue.ca)



## **About PENTHROX®**

PENTHROX® (methoxyflurane) is the only small, lightweight, handheld, fast-acting, inhaled analgesic that is self-administered under the supervision of the treating healthcare practitioner, indicated for the short-term relief of moderate to severe pain, associated with trauma or interventional medical procedures, in conscious adult patients. PENTHROX® provides rapid, effective pain relief in 5 minutes, with no need for needles and is not classified as an opioid. PENTHROX® allows patients to control their own pain relief by moderating the amount of PENTHROX® inhaled<sup>1</sup>.

## **About Purdue Pharma (Canada)**

Purdue Pharma (Canada) is a research-based pharmaceutical and consumer healthcare company which has operated in Canada for over 60 years. Its 400 employees are committed to improving the health and quality of life of Canadians. The company has a broad portfolio of prescription and non-prescription medications including: prescription treatments for pain, ADHD, chemotherapy-induced nausea and vomiting (CINV), various ophthalmic conditions and Consumer Healthcare products. The company supports evidence-based education for the safe use of its products. Its headquarters, located in Pickering, Ontario, include integrated research and development, formulation and manufacturing operations. Privately held and founded by physicians, Purdue Pharma (Canada) is independently associated with the worldwide Purdue/Napp/Mundipharma network of companies. Learn more at [www.purdue.ca](http://www.purdue.ca)

## **About Medical Developments International Ltd**

MDI is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MDI is a leader in emergency pain relief and respiratory products. The Company manufactures PENTHROX®, a fast-acting trauma & pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, sports medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MDI is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

<sup>1</sup> Purdue Pharma (Canada), [PENTHROX™ \(methoxyflurane\) Product Monograph](#), April 2018

<sup>2</sup> Medical Developments International (MDI). Periodic Safety Update Report number 005 for Methoxyflurane (Penthrox®), Nov .2017